Related references
Note: Only part of the references are listed.Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
M. Ilie et al.
ANNALS OF ONCOLOGY (2016)
Programmed Death Ligand-1 Immunohistochemistry-A New Challenge for Pathologists A Perspective From Members of the Pulmonary Pathology Society
Lynette M. Sholl et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration
Chan-Young Ock et al.
CLINICAL CANCER RESEARCH (2016)
Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma
Ching-Yao Yang et al.
EUROPEAN JOURNAL OF CANCER (2016)
Immune checkpoint therapy for non-small-cell lung cancer: an update
Bing Xia et al.
IMMUNOTHERAPY (2016)
Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer
Elisabeth Brambilla et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
Marius Ilie et al.
VIRCHOWS ARCHIV (2016)
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
Joseph McLaughlin et al.
JAMA ONCOLOGY (2016)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
Immune Checkpoint Modulation for Non-Small Cell Lung Cancer
Jean-Charles Soria et al.
CLINICAL CANCER RESEARCH (2015)
Stromal CD8+ T-cell Density-A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer
Tom Donnem et al.
CLINICAL CANCER RESEARCH (2015)
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N. Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The 2015 World Health Organization Classification of Lung Tumors Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers
Moon-Young Kim et al.
LUNG CANCER (2015)
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
Wendy A. Cooper et al.
LUNG CANCER (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells
Kathleen M. Mahoney et al.
CANCER IMMUNOLOGY RESEARCH (2015)
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
Lars Henning Schmidt et al.
PLOS ONE (2015)
Lung Squamous Cell Carcinomas with Basaloid Histology Represent a Specific Molecular Entity
Christian Brambilla et al.
CLINICAL CANCER RESEARCH (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours
Jerome Galon et al.
JOURNAL OF PATHOLOGY (2014)
Programmed death ligand-1 expression in non-small cell lung cancer
Vamsidhar Velcheti et al.
LABORATORY INVESTIGATION (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung
Jennifer M. Boland et al.
CLINICAL LUNG CANCER (2013)
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer
Marius Ilie et al.
CANCER (2012)
Genetic Changes in Squamous Cell Lung Cancer A Review
Rebecca S. Heist et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lung carcinomas with a basaloid pattern: a study of 90 cases focusing on their poor prognosis
D. Moro-Sibilot et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim et al.
LANCET (2008)
4-year mortality in patients with non-small-cell lung cancer: Development and validation of a prognostic index
Francois Blanchon et al.
LANCET ONCOLOGY (2006)
被撤回的出版物: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer (Retracted Article. See vol 356, pg 201, 2007)
Anil Potti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
REporting recommendations for tumour MARKer prognostic studies (REMARK)
LM McShane et al.
BRITISH JOURNAL OF CANCER (2005)
Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000
K Shibuya et al.
BMC CANCER (2002)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Share Paper
